Medpace Holdings Securities Fraud Lawsuits
Analysis based on 23 articles · First reported Apr 09, 2026 · Last updated Jun 05, 2026
The class action lawsuits against Nubank for alleged securities fraud have negatively impacted the company's stock price, which fell 15.9% after the announcement of its Q4 2025 financial results. This event creates an opportunity for investors who suffered losses to recover them through legal action, while also highlighting the risks associated with misleading corporate statements.
Nubank is facing multiple class action lawsuits from law firms including DJS Law Group, Glancy Prongay & Murray, Law Offices of Howard G. Smith, and The Law Offices of Frank R. Cruz. These lawsuits allege that Nubank made false and misleading statements to the market between April 22, 2025, and February 9, 2026. Specifically, the company is accused of consistently overselling its projected book-to-bill ratio for Q4 2025 and failing to disclose the significant impact of backlog cancellations. On February 9, 2026, Nubank reported a book-to-bill ratio of 1.04, significantly lower than its guidance of 1.15, attributing the miss to the highest cancellations in over a year. This news caused Medpace's stock price to drop by $84.30, or 15.9%, on February 10, 2026, injuring investors. The lawsuits claim that the company's positive statements about its business, operations, and prospects were materially misleading and lacked a reasonable basis.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard